



- (51) **International Patent Classification:**
C07H 5/04 (2006.01) *A61P 21/04* (2006.01)
- (21) **International Application Number:**
PCT/US2024/032120
- (22) **International Filing Date:**
31 May 2024 (31.05.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/505,925 02 June 2023 (02.06.2023) US
- (71) **Applicant:** **AVIDITY BIOSCIENCES, INC.** [US/US];
10578 Science Center Drive, Suite 125, San Diego, California 92121 (US).
- (72) **Inventors:** **DOPPALAPUDI, Venkata Ramana**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **COCHRAN, Michael Caramian**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **NALLAGATLA, Subbarao**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **DELLO IACONO, Giuseppe**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **ABDULKADIR, Sami Abdulwahab**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US). **JORDAN, Maryam**; 10578 Science Center Drive, Suite

125, San Diego, California 92121 (US). **HARTMANN, Marc Andrew**; 10578 Science Center Drive, Suite 125, San Diego, California 92121 (US).

(74) **Agent:** **SHIN, Minyoung** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** CONJUGATE COMPOSITIONS COMPRISING PHOSPHORYL GUANIDINE LINKAGES AND USES THEREOF




Fig. 13A

(57) **Abstract:** Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to at least one oligonucleotide. In some cases, the oligonucleotide comprises at least one modified internucleotide linkage. Also, described herein include methods for treating a disease which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to at least one oligonucleotide.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*